应用生物信息学方法分析肾透明细胞癌中FKBP11的表达

doi:10.6040/j.issn.1671-7554.0.2020.0367

Abstract

Abstract: Objective To explore the expression of FK506 binding protein 11(FKBP11)in clear cell renal cell carcinoma(ccRCC), and to analyze its correlation with the clinicopathological features of ccRCC. Methods Based on Ualcan, GEPIA and HPA databases, the mRNA and protein expressions of FKBP11 in ccRCC, their correlation with the clinicopathological features of ccRCC, and their effects on the prognosis of patients were analyzed. Results The mRNA expression of FKBP11 was higher in ccRCC tissues than in normal kidney tissues. Analysis of Ualcan database showed differences in FKBP11 expression between normal kidney tissues and Grade 1(P=5.78E-051), Grade 2(P=1.62E-12), Grade 3(P=1.11E-16)and Grade 4(P=1.63E-12)ccRCC. The expression differences between normal and ccA and ccB subtypes were both P=1.62E-12. There were differences between normal and N0(P<1E-12)and N1(P=8.26E-05)subtypes in TNM staging. With higher ccRCC pathological grading, the expression of FKBP11 was up-regulated and related to the progression of ccRCC. However, there were no differences among different age, sex and race groups(P>0.05). There was difference in the overall survival rate between patients with high and low expressions of FKBP11(P<0.01). Conclusion Bioinformatics analysis indicated that FKBP11 was highly expressed in ccRCC, and there were differences in FKBP11 expressions among different stages, pathological grades and subtypes of ccRCC. Poorer pathological grades and stages of ccRCC showed higher expression of FKBP11, and high expression of FKBP11 indicated poorer prognosis.

Key words: FK506-binding protein-11, Clear cell renal cell carcinoma, Bioinformatics, Prognosis

CLC Number:

R737.11

LI Yinglin, SONG Daoqing, XU Zhonghua. Identification of FKBP11 expression in clear cell renal cell carcinoma using bioinformatics analysis[J].Journal of Shandong University (Health Sciences), 2020, 58(9): 45-51.

References 32

[1]	Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions [J]. CA Cancer J Clin, 2017, 67(6): 507-524.
[2]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[3]	Ge Y, Xu A, Zhang M, et al. FK506 binding protein 10 is overexpressed and promotes renal cell carcinoma [J]. Urol Int, 2017, 98(2): 169-176.
[4]	Yang WS, Moon HG, Kim HS, et al. Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer [J]. J Proteome Res, 2012, 11(2): 1078-1088.
[5]	Knuppel L, Heinzelmann K, Lindner M, et al. FK506-binding protein 10(FKBP10)regulates lung fibroblast migration via collagen VI synthesis [J]. Respir Res, 2018, 19(1): 67. doi: 10.1186/s12931-018-0768-1.
[6]	Romano S, Staibano S, Greco A, et al. FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential [J]. Cell Death Dis, 2013, 4(4): e578. doi: 10.1038/cddis.2013.109.
[7]	Wang RG, Zhang D, Zhao CH, et al. FKBP10 functioned as a cancer-promoting factor mediates cell proliferation, invasion, and migration via regulating PI3K signaling pathway in stomach adenocarcinoma [J]. Kaohsiung J Med Sci, 2020, 36(5): 311-317.
[8]	Daudt DR, Yorio T. FKBP51 protects 661w cell culture from staurosporine-induced apoptosis [J]. Mol Vis, 2011, 17:1172-1181. Epub 2011 May 4.
[9]	Romano S, Dangelillo A, Staibano S, et al. FK506-binding protein 51 is a possible novel tumoral marker [J]. Cell Death Dis, 2010, 1(7): e55. doi: 10.1038/cddis.2010.32.
[10]	Lin IY, Yen CH, Liao YJ, et al. Identification of FKBP11 as a biomarker for hepatocellular carcinoma [J]. Anticancer Res, 2013, 33(6): 2763-2769.
[11]	Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses [J]. Neoplasia, 2017, 19(8): 649-658.
[12]	Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses [J]. Nucleic Acids Res, 2017,45(W1): W98-W102.
[13]	Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome [J]. Protein Sci, 2018, 27(1): 233-244.
[14]	Lipworth L, Tarone RE, Mclaughlin JK. The epidemiology of renal cell carcinoma [J]. J Urol, 2006, 176(6 Pt 1): 2353-2358.
[15]	Flanigan RC, Campbell SC, Clark JI, et al. Metastatic renal cell carcinoma [J]. Curr Treat Options Oncol, 2003, 4(5): 385-390.
[16]	魏先, 胡志全. 转移性肾细胞癌免疫治疗进展[J]. 现代泌尿生殖肿瘤杂志, 2017, 9(1): 1-4.
[17]	Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors [J]. Cancer, 2010, 116(18): 4256-4265.
[18]	Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial [J]. J Clin Oncol, 2010, 28(6): 1061-1068.
[19]	Ramadori G, Ioris RM, Villanyi Z, et al. FKBP10 Regulates Protein Translation to Sustain Lung Cancer Growth [J]. Cell Rep, 2020, 30(11): 3851-3863.
[20]	Brebi P, Maldonado L, Noordhuis MG, et al. Genome-wide methylation profiling reveals Zinc finger protein 516(ZNF516)and FK-506-binding protein 6(FKBP6)promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population [J]. Epigenetics, 2014, 9(2): 308-317.
[21]	Yao YL, Liang YC, Huang HH, et al. FKBPs in chromatin modification and cancer [J]. Curr Opin Pharmacol, 2011, 11(4): 301-307.
[22]	Chen YG, Liu F, Massague J. Mechanism of TGFbeta receptor inhibition by FKBP12 [J]. EMBO J, 1997, 16(13): 3866-3876.
[23]	Xu X, Su B, Barndt RJ, et al. FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506 [J]. Transplantation, 2002, 73(11): 1835-1838.
[24]	Fan G, Yang Y, Li T, et al. A Phytophthora capsici RXLR Effector Targets and Inhibits a Plant PPIase to Suppress Endoplasmic Reticulum-Mediated Immunity [J]. Mol Plant, 2018, 11(8): 1067-1083.
[25]	Chen H, Zhang W, Sun X, et al. Fkbp1a controls ventricular myocardium trabeculation and compaction by regulating endocardial Notch1 activity [J]. Development, 2013, 140(9): 1946-1957.
[26]	Lietman CD, Lim J, Grafe I, et al. Fkbp10 deletion in osteoblasts leads to qualitative defects in bone [J]. J Bone Miner Res, 2017, 32(6): 1354-1367.
[27]	Liu FL, Liu TY, Kung FL. FKBP12 regulates the localization and processing of amyloid precursor protein in human cell lines [J]. J Biosci, 2014, 39(1): 85-95.
[28]	Chambraud B, Sardin E, Giustiniani J, et al. A role for FKBP52 in Tau protein function [J]. Proc Natl Acad Sci U S A, 2010, 107(6): 2658-2663.
[29]	Rulten SL, Kinloch RA, Tateossian H, et al. The human FK506-binding proteins: characterization of human FKBP19 [J]. Mamm Genome, 2006, 17(4): 322-331.
[30]	Zhang K, Wang S, Malhotra J, et al. The unfolded protein response transducer IRE1alpha prevents ER stress-induced hepatic steatosis [J]. EMBO J, 2011, 30(7): 1357-1375.
[31]	Lu H, Yang Y, Allister EM, et al. The identification of potential factors associated with the development of type 2 diabetes: a quantitative proteomics approach [J]. Mol Cell Proteomics, 2008, 7(8): 1434-1451.
[32]	Ruer-Laventie J, Simoni L, Schickel JN, et al. Overexpression of Fkbp11, a feature of lupus B cells, leads to B cell tolerance breakdown and initiates plasma cell differentiation[J]. Immun Inflamm Dis, 2015, 3(3): 265-279.

Metrics

Viewed

Full text

315

HTML			PDF

Just accepted	Online first	Issue	Just accepted	Online first	Issue
0	0	0	0	0	315

From	Others	local

Times	34	281
Rate	11%	89%

Abstract

1476

Just accepted	Online first	Issue

0	0	1476

	From	Others

	Times	1476
	Rate	100%

Cited

Web of Science	Crossref	ScienceDirect	Search for Citations in Google Scholar >>


This page requires you have already subscribed to WoS.

Shared

Discussed

Comments

Recommended 0

No Suggested Reading articles found!

Identification of FKBP11 expression in clear cell renal cell carcinoma using bioinformatics analysis

PDF (PC)

Abstract

Cite this article

share this article

References 32

Related Articles 2

Metrics

Comments

Recommended 0

[1]	SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(7): 47-52.
[2]	LUO Xin, HE Bing, NIE Qingsheng, HOU Zhenbo, DONG Jun, LI Yuhua, ZENG Xiangqin, LIU Wei, KONG Demin, CAO Jinfeng. Comparison of the value of mono-exponential mode and diffusion kurtosis imaging mode in grading clear cell renal cell carcinoma using magnetic resonance diffusion-weighted imaging [J]. Journal of Shandong University (Health Sciences), 2020, 58(7): 89-95.